Seroba Kernel
Press Archives
2009 Press Releases
2008 Press Releases
2007 Press Releases
2006 Press Releases
2005 Press Releases
2004 Press Releases
2002 Press Releases

2007 Press
18th December
Merrion Pharmacueticals Plc admitted to the IEX
29th November
Alimentary Health’s Probiotic Technology Increased Availability In Stores – Marketed as Align® by Procter & Gamble
22nd November
Opsona Therapeutics Ltd In-Licenses Novel Anti-Inflammatory Modular from Nestle
20th November
Alimentary Health announces commencement of Clinical Study in Acute Diverticulitis
16th October
Recent Study Confirms Alimentary Health's Bifantis® Demonstrates Efficacy in the Treatment of Irritable Bowel Syndrome
18th September
Novate Medical Ltd secures €4m funding from ACT Venture Capital, Seroba Bioventures and Enterprise Ireland
12th September
FDA accepts IND filing for arverapamil (AGI-003) Phase III programme
15th August
Alimentary Health Announces Additional Clinical Studies Evaluation Agreement with Procter & Gamble
17th July
Alimentary Health Probiotic Now Available to U.S Pharmacits
8th June
Crescent Diagnostics Announces Positive Clinical Results for its Novel Bone Quality Test, BQT™
11th April
AGI Therapeutics plc FDA approval to file IND for Arverapamil Phase III study
11th April
AGI Therapeutics, plc Financial results for the twelve months ended 31 December 2006
15th February
Product update and outlook for 2007
1st February
Preliminary clinical data for mecamylamine (AGI-004) and arbaclofen (AGI-006)
25th January
Deerac Fluidics launches new high throughput liquid handling system
Alimentary Health Announces Additional Clinical Studies Evaluation Agreement with Procter & Gamble


Cork Ireland, August 15th, 2007 Alimentary Health Ltd. (AH), a development stage specialty biotechnology company, announces that it has signed an agreement with Procter and Gamble (NYSE:PG) that will see AH probiotic technology receive further clinical evaluation in specific Gastrointestinal (GI) indications.

AH is a leader in pioneering the development of safe and effective therapeutics for GI and other indications. AH probiotic technology such as Bifantis® (Bifidobacterium infantis 35624), has been clinically proven to manage a full range of episodic digestive upsets, including constipation, diarrhea, abdominal discomfort, urgency, gas and bloating. Bifantis is only found in the daily probiotic supplement Align® which is being marketed by P&G in the US under a current licensing agreement with AH. This new Clinical Studies Agreement is designed to further explore the clinical benefits of AH technology over the next several years.

Under the terms of the agreement, AH would be entitled to receive undisclosed milestone payments based upon clinical performance.

Barry Kiely, CEO of Alimentary Health, said "today’s announcement that Procter & Gamble has chosen to undertake further clinical evaluation for Alimentary’s probiotic technology reflects the successful relationship we have had with the company since 2001. This project will focus on evaluating the clinical benefits of AH’s probiotic technology for gastrointestinal indications. We are delighted to extend and expand our relationship with Procter & Gamble and look forward to updating our stakeholders on our progress."

About Alimentary Health Ltd.

Alimentary Health is a development stage specialty biotechnology company located in Ireland. The company is focused on the discovery, development and commercialization of proprietary probiotic and pharmabiotic treatments for gastrointestinal disorders and other inflammatory conditions. Alimentary Health is the foundation industry partner of the Alimentary Pharmabiotic Center based at University College Cork, Ireland.

For further information please see www.alimentaryhealth.ie

Email: info@ahealth.ie